Advertisement
Advertisement
October 2, 2012
Boston Scientific's Promus Element Plus BTK Launched in Europe
September 24, 2012—Boston Scientific Corporation (Natick, MA) announced the European launch of the Promus Element Plus below-the-knee (BTK) everolimus-eluting stent system for the treatment of certain severe peripheral artery lesions. The Promus Element Plus BTK is indicated for the treatment of critical limb ischemia (CLI) or severe lower leg claudication in infrapopliteal lesions. The device has CE Mark approval for both monorail and over-the-wire versions and will be available immediately.
According to the company's press release, the everolimus drug and polymer used on the Promus Element Plus BTK stent have been studied in multiple coronary randomized clinical trials and registries; the platinum chromium alloy is designed specifically for stenting and enhanced visibility and conformability, along with less recoil and higher radial strength. The device's low-profile delivery system is designed to facilitate precise stent placement across challenging lesions.
“The drug-eluting stent is an important additional tool that I use to address focal stenosis in the arteries below the knee and ultimately reduce amputation rates in CLI and claudicant patients,” commented Martin Kamarád, MD, in the company's press release. Dr. Kamarád is associated with the Podlesí Hospital in Trinec, Czech Republic. He continued, “In addition to the benefits of drug delivery, I believe the Promus Element Plus BTK stent offers significant advantages in terms of properties in the design and higher resistance to compression and less recoil thanks to its unique platinum-chromium alloy and stent architecture.”
Advertisement
Advertisement
